34846 Federal Register / Vol. 61, No. 129 / Wednesday, July 3, 1996 / Notices

Dated: June 27, 1996.

Joseph R. Carter

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–16946 Filed 7–02–96; 8:45 am]

BILLING CODE 4163–18–P

Administration for Children and

Families

Submission for OMB Review;

Comment Request

Title: Annual Survey of Refugees

(ORR–9).

OMB No.: 0970–0033.

Description: The Annual Survey of

Refugees collects information on the

economic circumstances of a random

sample of refugees, Amerasians, and

entrants who arrived in the U.S. during

the previous five years. The survey

focuses on their training, labor force

participation, and welfare utilization

rates. Data are segmented by region of

origin, State of resettlement, and

number of months since arrival. From

their responses, ORR reports on the

economic adjustment of refugees annual

deliberations of refugee admissions and

funding and by program managers in

formulating policies for the direction of

the Refugee Resettlement Program.

Respondents: State governments.

ANNUAL BURDEN ESTIMATES

Instrument

Number of

respondents

Number

of responses

per respondent

Average

burden

hours

per respondent

Total

burden

hours

ORR–9 ............................................................................................................................................................ 1,800 1 .75 1,350

Estimated Total Annual Burden Hours:

1,350.

Additional Information

Copies of the proposed collection may

be obtained by writing to the

Administration for Children and

Families, Office of Information Services,

Division of Information Resource

Management Services, 370 L’Enfant

Promenade, S.W., Washington, D.C.

20447, Attn: ACF Reports Clearance

Officer.

OMB Comment

OMB is required to make a decision

concerning the collection of information

between 30 and 60 days after

publication of this document in the

Federal Register. Therefore, a comment

is best assured of having its full effect

if OMB receives it within 30 days of

publication. Written comments and

recommendations for the proposed

information collection should be sent

directly to the following:

Office of Management and Budget,

Paperwork Reduction Project, 725

17th Street, N.W., Washington, D.C.

20503, Attn: Ms. Wendy Taylor.

Dated: June 26, 1996.

Larry Guerrero,

Director, Office of Information Management

Services.

[FR Doc. 96–16969 Filed 7–2–96; 8:45 am]

BILLING CODE 4184–01–M

Food and Drug Administration

[Docket No. 96N–0158]

Agency Information Collection

Activities; Proposed Collection;

Comment Request

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing an

opportunity for public comment on the

proposed collection of certain

information by the agency. Under the

Paperwork Reduction Act of 1995,

Federal agencies are required to publish

a notice in the Federal Register

concerning each collection of

information and to allow 60 days for

public comment in response to the

notice. This notice solicits comments on

a survey of hormone replacement

therapy (HRT) among women with a

previous diagnosis of endometrial

cancer.

DATES: Submit written comments on the

collection of information by September

3, 1996.

ADDRESSES: Submit written comments

on the collection of information to the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

12420 Parklawn Dr., rm. 1–23,

Rockville, MD 20857. All comments

should be identified with the docket

number found in brackets in the

heading of this document.

FOR FURTHER INFORMATION CONTACT:

Charity B. Smith, Office of Information

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, rm. 16B–19, Rockville,

MD 20857, 301–827–1686.

SUPPLEMENTARY INFORMATION: Section

3506(c)(2)(A) of the Paperwork

Reduction Act of 1995 (44 U.S.C.

3506(c)(2)(A)) requires Federal agencies

to provide a 60-day notice in the

Federal Register concerning each

proposed collection of information.

‘‘Collection of information’’ is defined

in 44 U.S.C. 3502(3) and 5 CFR

1320.3(c). To comply with this

requirement, FDA is publishing notice

of the proposed collection of

information listed below.

With respect to the following

collection of information, FDA invites

comments on: (1) Whether the proposed

collection of information is necessary

for the proper performance of FDA’s

functions, including whether the

information will have practical utility;

(2) the accuracy of FDA’s estimate of the

burden of the proposed collection of

information, including the validity of

the methodology and assumptions used;

(3) ways to enhance the quality, utility,

and clarity of the information to be

collected; and (4) ways to minimize the

burden of the collection of information

on respondents, including through the

use of automated collection techniques,

when appropriate, and other forms of

information technology.

Survey of HRT Among Women With A

Previous Diagnosis of Endometrial

Cancer

Under FDA’s statutory authority to

conduct and sponsor research (21 U.S.C.
Federal Register / Vol. 61, No. 129 / Wednesday, July 3, 1996 / Notices 34847

393(b)(2)(C) and 42 U.S.C. 300u–1), FDA

and the Fred Hutchinson Cancer

Research Center in Seattle, WA, have

jointly designed a study involving a

written survey to be completed by

women with a previous diagnosis of

endometrial cancer. The study will

evaluate the occurrence of menopausal

vasomotor symptoms (‘‘hot flashes’’)

among these women, and the extent to

which they have used HRT, either as

therapy for menopausal symptoms or for

other reasons. (‘‘Hormone replacement

therapy’’ means treatment with estrogen

alone or with a combination of estrogen

and progestogen.)

FDA estimates the burden of this survey

as follows:

ESTIMATED ANNUAL REPORTING BURDEN

No. of Respondents Annual Frequency per

Response Total Annual Responses Hours per Response Total Hours

575 1 575 .5 288

There are no capital costs or operating and maintenance costs associated with this collection.

Dated: June 26, 1996.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 96–16884 Filed 7–2–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96N–0186]

Agency Information Collection

Activities: Proposed Collection;

Comment Request

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing an

opportunity for public comment on the

proposed collection of certain

information by the agency. Under the

Paperwork Reduction Act of 1995,

Federal agencies are required to publish

notice in the Federal Register

concerning each proposed collection of

information and to allow 60 days for

public comment in response to the

notice. This notice solicits comments on

a proposed survey of mammography

facilities to assess the impact of

proposed regulations required by the

Mammography Quality Standards Act of

1992 (the MQSA).

DATES: Submit written comments on the

collection of information by September

3, 1996.

ADDRESSES: Submit written comments

on the collection of information to the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

12420 Parklawn Dr., rm. 1–23,

Rockville, MD 20857. All comments

should be identified with the docket

number found in brackets in the

heading of this document.

FOR FURTHER INFORMATION CONTACT:

Charity B. Smith, Office of Information

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, rm. 16B–19, Rockville,

MD 20857, 301–827–1686.

SUPPLEMENTARY INFORMATION: Section

3506(c)(2)(A) of the Paperwork

Reduction Act of 1995 (44 U.S.C.

3506(c)(2)(A)) requires Federal agencies

to provide a 60-day notice in the

Federal Register concerning each

proposed collection of information.

‘‘Collection of information’’ is defined

in 44 U.S.C. 3502(3) and 5 CFR

1320.3(c). To comply with this

requirement, FDA is publishing notice

of the proposed collection of

information listed below.

With respect to the following

collection of information, FDA invites

comments on: (1) Whether the proposed

collection of information is necessary

for the proper performance of FDA’s

functions, including whether the

information will have practical utility;

(2) the accuracy of FDA’s estimate of the

burden of the proposed collection of

information, including the validity of

the methodology and assumptions used;

(3) ways to enhance the quality, utility,

and clarity of the information to be

collected; and (4) ways to minimize the

burden of the collection of information

on respondents, including through the

use of automated collection techniques,

when appropriate, and other forms of

information technology.

FDA Survey of Mammography Facilities

The MQSA of 1992 (Pub. L. 102–539)

has resulted in regulatory efforts by FDA

to ensure high quality standards for

mammography in the United States. In

the Federal Register of April 3, 1996 (61

FR 14856), FDA proposed final

regulations to implement these

standards. Interim regulations are

codified at 21 CFR 900. In connection

with this rulemaking, FDA proposes to

conduct a survey of facilities to

determine current operating costs and

procedures. The information to be

collected from the proposed survey

includes general provider

characteristics, equipment

characteristics, facility operating

procedures, personnel qualifications,

and costs of compliance with current

quality standards. This information is

necessary in order to ensure that costs

to affected facilities are minimized to

the extent consistent with maintenance

of high quality mammography services,

and that patient access to

mammography services is not

diminished as a result of agency action.

The proposed survey will be a onetime data collection effort. Surveys will

be mailed to 1,000 randomly selected

facilities. Facilities will be contacted by

telephone in order to respond to any

specific issues, or questions that may

arise. Responses will not be mandatory,

and no facility will be required to

respond. All responses will be kept

confidential, although a compilation of

data that does not reveal facility-specific

information will be made available

upon request to participants and to the

public. A toll-free telephone number

will be installed to allow respondents

the opportunity to call if specific issues

arise.

FDA estimates the burden of this onetime survey as follows:

ESTIMATED ANNUAL REPORTING BURDEN

Burden Element No. of

Respondents

Annual

Frequency per

Response

Total Annual

Responses

Hours per

Response Total Hours Total Costs

Initial Contact by Telephone 1,000 1 1,000 0.083 83 $1,385

Compile Requested Information 702 1 702 1.0 702 $11,716